Todays Report: Today, Clovis Oncology Inc. (CLVS) Upgrade to Buy at Vetr Inc.

Today, Clovis Oncology Inc. (CLVS) Upgrade to Buy at Vetr Inc.

Vetr upgraded shares of Clovis Oncology Inc. (NASDAQ:CLVS) from a sell rating to a buy rating in a research report report published on Monday morning. The brokerage currently has $39.27 price objective on the biopharmaceutical company’s stock.

CLVS has been the subject of several other reports. SunTrust Banks Inc. lifted their price target on Clovis Oncology from $38.00 to $50.00 and gave the company a buy rating in a research report on Friday, September 23rd. Piper Jaffray Cos. reiterated a neutral rating and issued a $42.00 price target on shares of Clovis Oncology in a research report on Wednesday, October 12th. Zacks Investment Research cut Clovis Oncology from a buy rating to a hold rating in a research report on Tuesday, October 4th. Credit Suisse Group AG reiterated an outperform rating and issued a $41.00 price target on shares of Clovis Oncology in a research report on Monday, October 10th. Finally, Stifel Nicolaus reiterated a buy rating and issued a $45.00 price target on shares of Clovis Oncology in a research report on Monday, October 17th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $36.41.

Clovis Oncology (NASDAQ:CLVS) opened at 34.39 on Monday. The firm’s market cap is $1.33 billion. The firm has a 50-day moving average price of $32.38 and a 200-day moving average price of $23.00. Clovis Oncology has a one year low of $11.57 and a one year high of $40.29.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.95) by $0.25. During the same period in the previous year, the firm earned ($2.62) earnings per share. On average, equities analysts expect that Clovis Oncology will post ($8.97) EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. State Board of Administration of Florida Retirement System increased its position in Clovis Oncology by 8.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 22,819 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 1,693 shares in the last quarter. DekaBank Deutsche Girozentrale increased its position in Clovis Oncology by 38.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 22,800 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 6,300 shares in the last quarter. Swiss National Bank increased its position in Clovis Oncology by 12.7% in the second quarter. Swiss National Bank now owns 55,050 shares of the biopharmaceutical company’s stock valued at $755,000 after buying an additional 6,200 shares in the last quarter. California State Teachers Retirement System increased its position in Clovis Oncology by 13.1% in the second quarter. California State Teachers Retirement System now owns 66,645 shares of the biopharmaceutical company’s stock valued at $914,000 after buying an additional 7,702 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Clovis Oncology by 8.1% in the second quarter. Bank of New York Mellon Corp now owns 164,735 shares of the biopharmaceutical company’s stock valued at $2,260,000 after buying an additional 12,305 shares in the last quarter.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

Related posts

Leave a Comment